UNSPSC 51332876: Thioproperazine mesylate

This classification denotes an antipsychotic agent with the molecular formula C22H30N4O2S2.2CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 71P630M192, chemically known as phenothiazine-2-sulfonamide, n,n-dimethyl-10-(3-(4-methyl-1-piperazinyl)propyl)-, dimethanesulfonate but more generally known as thioproperazine mesilate, which bears US NIH Compound Identifier 92178. Most nations, for tariff and trade purposes, schedule thioproperazine mesylate under HS 29350090.

As of Q4 2014, THIOPROPERAZINE MESYLATE remains US FDA's Preferred Term for this commodity. Thioproperazine mesylate bears US NLM identifiers UMLS ID C0770896 and NCI Concept Code C80010. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O.

UNSPSC 51332876 Thioproperazine mesylate is a Commodity code that does not reflect the actual pharmaceutical procurement activity currently posted under it. Recent state and local solicitations tagged with this code focus on naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are thioproperazine mesylate. State and local health departments, cooperative purchasing alliances, and county health agencies are the primary issuing bodies, with activity spanning single-jurisdiction health initiatives and multi-state cooperative purchasing programs. The solicitations represent three distinct procurement models: a direct county health purchase, a state-level exploratory RFI to assess direct manufacturer relationships, and a multi-state cooperative contract vehicle serving participating government facilities.

Recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit managers and group purchasing organizations; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon. Activity clusters in Florida, Texas, and the MMCAP member states. The code shows minimal relevance to thioproperazine mesylate and appears to be a tagging mismatch; firms pursuing pharmaceutical procurement under this code should verify actual category assignments before planning business development efforts.